stockrow
Saturday 7 November 2026
Export INBX’s income statement to Excel — free account
Inhibrx Biosciences, Inc.
INBX Healthcare Biotechnology
Inhibrx Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.3 million, up 550.0% from fiscal 2024.
- Revenue
- +992.4%
- EPS
- −26.5%
- Free cash flow
- +0.12%
- Total debt
- +77.6%
Quarter to June 2026, against a year earlier
85.46
5.18
+6.45%
Follow INBX
Alert me
Inhibrx Biosciences, Inc. (INBX) P/E ratio
Inhibrx Biosciences, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.2× (September 2024) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.1× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2025 | 0.0× | — |
| Dec 2024 | 0.1× | 6.89% |
| Jun 2024 | 0.1× | — |
| Dec 2023 | 0.0× | — |
| 2 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.2×
Ten-year median
0.0×
Current reading's percentile
59
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| RAPP Rapport Therapeutics, Inc. compare | n/m |
| VOR Vor Biopharma Inc. compare | n/m |
| VSTM Verastem, Inc. compare | n/m |
| DRTS Alpha Tau Medical Ltd. compare | n/m |
| INBX Inhibrx Biosciences, Inc. | n/m |
| MNKD MannKind Corporation compare | n/m |
| LBRX LB Pharmaceuticals Inc compare | n/m |
| SGP SpyGlass Pharma, Inc. compare | n/m |
| AVLN Avalyn Pharma Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)